BPC-157
Synthetic peptide derived from a stomach protein. Used to speed up tendon, ligament, and gut healing.
BPC-157: Synthetic peptide derived from a stomach protein. Used to speed up tendon, ligament, and gut healing. Think of BPC-157 as a healing accelerator for connective tissue.
Think of BPC-157 as a healing accelerator for connective tissue. Most users run it for stubborn tendon, ligament, or gut problems where regular rehab has stalled. You inject a tiny amount under the skin once a day for 4-6 weeks, take a break, then reassess.
FDA's advisory committee voted 8 to 6 on July 23, 2026 to recommend it for the 503A list, against the recommendation of FDA's review staff. That vote is advisory and does not bind FDA. Adding a substance requires rulemaking, which has not happened.
Not prescribed in conventional medicine. Some compounding pharmacies and longevity clinics offer it off-label.
Who it's for
- →Lifters with nagging tendon or joint pain
- →Anyone recovering from a soft-tissue injury
- →People dealing with gut issues (oral form)
What to expect
- Week 1
Often nothing yet, sometimes mild head-rush at injection.
- Week 4
Most users notice the original injury feels notably less reactive.
- Week 8
Full effect for the cycle. Plateau, then take a break.
Looking at BPC-157? Your next 3 steps
- 1Work out your syringe units
Vial size + BAC water turns into the exact units to draw for BPC-157.
Open calculator → - 2See what to stack & monitor
The companion supplements and the bloodwork worth tracking on this kind of protocol.
Bloodwork guide → - 3Save it & ask the Coach
A free account gets you Coach questions every day, free; membership saves your stack and makes the Coach stack-aware.
Create free account →
How it works (mechanism)
Promotes angiogenesis (new blood vessel growth) and accelerates fibroblast / endothelial cell migration to injury sites. Also modulates the nitric oxide pathway and protects against gut-wall damage. Most effects appear at the local injection site rather than systemically.
Dosing protocol
Stacks well with
Stack essentials
Side effects
When NOT to use
- ⚠Active malignancy (theoretical)
- ⚠Pregnancy / nursing (no data)
Common mistakes
- • Running it indefinitely instead of cycling
- • Underdosing (under 200mcg often blunts the response)
- • Leaving reconstituted vial at room temp longer than 7 days
What it actually is
BPC-157 is a synthetic fragment of a protein found in human gastric juice — the name stands for Body Protection Compound. It does not exist as such in nature; researchers isolated a 15-amino-acid stretch of a larger stomach protein and found that fragment did interesting things in animals. It is not approved as a medicine anywhere, and FDA has explicitly placed it in the category of substances that cannot lawfully be compounded, which is the single most important regulatory fact about it.
The proposed mechanism is angiogenic: it appears to promote formation of new blood vessels into damaged tissue, largely through the VEGF pathway, and to modulate growth-factor signalling and nitric oxide. More blood supply into a poorly-vascularised tendon or ligament would plausibly speed repair, and tendon is exactly the tissue that heals slowly because it has so little blood supply. That is a coherent story and it is almost entirely built on rodent work.
Forms, and which is which
The route the animal literature and essentially all user protocols use. Requires reconstitution from lyophilised powder.
Verdict: The form with what evidence there is, such as it is.
Marketed for intestinal issues on the logic that a gastric-derived peptide might act locally in the gut. Systemic absorption of an intact peptide from the gut is the obvious problem, and it has not been demonstrated in people.
Verdict: Plausible only for a local gut effect; do not expect systemic action.
A salt form claimed to have better stability in solution. The stability claim is chemistry rather than clinical evidence — it says nothing about whether the peptide works.
Verdict: A formulation difference, not an efficacy difference.
Sold pre-mixed. Combining two compounds with no human efficacy evidence produces no human efficacy evidence, and makes it impossible to attribute anything you notice.
Verdict: Convenient, and analytically worse than running one thing.
What it is claimed to do, graded
This is the primary reason people take it and there is no completed human trial demonstrating it. The evidence is rodent tendon and ligament models, which are consistent and genuinely interesting, and which have not translated.
The strongest animal literature is here — it is a gastric peptide and the rodent gut data is the most extensive it has. One human trial in ulcerative colitis was presented only as a conference abstract decades ago and never published in full; FDA's own review says it does not support effectiveness.
Consistently reported by users and untested in any controlled trial. Reduced pain and accelerated healing are also not the same thing, and users routinely conflate them.
Demonstrated in rodents. No human data.
Grades describe how much human evidence exists for that specific claim, not whether it will work for you or whether it is safe.
Pros and cons
- • The animal literature is unusually consistent across labs and injury models, which is not true of most research peptides
- • Reported side effects at commonly used amounts are mild, though nobody has looked systematically
- • Cheap and widely available relative to other research peptides
- • The mechanism is coherent and addresses a real problem — tendon heals badly because it is poorly vascularised
- • Zero completed human efficacy trials, for the use it is overwhelmingly taken for
- • FDA placed it in the 503A category that cannot be lawfully compounded, so the legal supply route closed
- • Everything sold is research-chemical supply with unverified identity, purity and sterility
- • The angiogenic mechanism is the same reason the theoretical cancer concern exists — new blood vessels are not selectively good
When to stop
- • Any new or growing lump, unexplained weight loss, or persistent unexplained symptom — given the angiogenesis concern, that warrants assessment rather than watching.
- • Injection site redness, heat, swelling or pain that worsens rather than settles: that is infection, and unverified sterility makes it a real risk.
- • Any sign the injury is worsening rather than improving — pain that increases, or function that declines, means the injury needs a diagnosis, not a peptide.
- • If eight weeks have passed with no change, the honest conclusion is that it is not working for you.
Interactions
The proposed mechanism promotes new blood vessel formation. Tumours also require new blood vessels to grow. This is theoretical rather than demonstrated, and it is the most serious concern on the page.
Effects on nitric oxide and vascular signalling are proposed. No human interaction data exists, which is not the same as no interaction.
No safety data of any kind.
Blends make it impossible to attribute an effect or a reaction to a specific compound.
Is this for you?
- • You have already had the injury properly diagnosed and are considering this alongside — not instead of — actual rehabilitation
- • You accept you are acting on rodent data and can afford for it to be worth nothing
- • You understand what you are buying is unverified research-chemical supply
- • You have a personal or family history of cancer — the angiogenic mechanism is the specific concern
- • You have not had the injury looked at, and are using this instead of finding out what is wrong
- • You expect the gut evidence to transfer to your tendon, or the reverse
- • You are pregnant, breastfeeding or trying to conceive
The one number
Sources for the claims above
- FDA reviewed BPC-157 and concluded the available human material does not support effectiveness; it is in the 503A category that cannot be lawfully compounded from bulk.FDA bulk drug substances review and 503A category listing
- The advisory committee voted to recommend BPC-157 for the 503A list in July 2026, against FDA review staff advice. That vote is advisory, does not bind FDA, and no rulemaking has followed.FDA Pharmacy Compounding Advisory Committee, July 2026
- The tendon and ligament healing evidence is rodent-model work.
- Systematic review of use in orthopaedic sports medicine finds no completed human efficacy trials.
- Narrative review weighing claimed regeneration against the risks of unregulated supply.
Drug & supplement interactions
- ⚠Limited documented drug interactions
- ⚠Some users report compounded effect with NSAIDs (no published data)
- ⚠Theoretical caution with pro-angiogenic compounds in malignancy contexts
The Pepdex take
Pepdex take: 250mcg/day for 5 weeks is the sweet spot for chronic shoulder. Minor change by week 3, real change by week 5. Bilateral injection near the joint outperforms distal abdominal injection in community reports, the local-injection question is still debated in the literature, but for tendon work, near-the-injury wins for most users. Don't bother running below 200mcg, it doesn't crack the threshold reliably.
Community patterns
New to BPC-157? Grab the starter checklist.
Drop your email and we'll send the one-page starter checklist beginners actually need first. No account needed.
No spam, and we never sell your email. Just the checklist. Email support@pepdex.co to opt out any time.
Numbers redacted in this preview. Members get the full answer, on their own stack.
Ask the Coach anything about BPC-157 or your own stack. This is it working.
Trained only on Pepdex content. Does the dose math, flags interactions, knows your stack. Won't push vendors, won't pretend to be a doctor.
Unlock the full Coach, from $4.99/week →Frequently asked
What is BPC-157?+
Is BPC-157 FDA approved?+
Is BPC-157 legal?+
Is BPC-157 banned by WADA?+
Are you still natty after taking BPC-157?+
Do doctors prescribe BPC-157?+
What's the typical dose of BPC-157?+
What are the side effects of BPC-157?+
How long until BPC-157 starts working?+
What can you stack with BPC-157?+
Where do people get BPC-157?+
BPC-157 vs TB-500, which is better?+
BPC-157 vs GHK-Cu, which is better?+
Common questions about BPC-157
Head-to-head with BPC-157
Tracked alongside BPC-157
Same goal, different aisle — each graded on its own evidence in the Pepdex catalog.
More in Healing
A fragment of Thymosin Beta-4. Drives cell migration and tissue repair, used for chronic soft-tissue stuff.
A bone-building drug. A parathyroid-hormone fragment (PTH 1-34), FDA-approved as Forteo for severe osteoporosis; Abaloparatide (Tymlos) is its newer sibling analog. Anabolic for bone, the opposite of bisphosphonates.
A compound studied for calming nerve pain and inflammation without raising red blood cells. An EPO-derived peptide that targets the innate-repair receptor without the red-blood-cell side of erythropoietin, studied for neuropathic pain, sarcoidosis, and diabetic complications.
A gut drug that helps people with short bowel syndrome absorb more nutrients. A recombinant GLP-2 analog, FDA-approved in 2012 for short bowel syndrome with intestinal failure; it hits a different receptor and indication than the GLP-1 weight-loss drugs.